Spyre Therapeutics (SYRE) Files Mixed Shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month high with Hormuz transits in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- Microsoft pulls out of UK Nscale data centre deal over power delay
- Eos Energy Q3 2026 preliminary revenue up 169% year over year
Form S-3 Spyre Therapeutics, Inc.
February 27, 2025 4:25 PM ESTAs filed with the Securities and Exchange Commission on February 27, 2025. Registration No.... More



